Literature DB >> 26849401

Same sibling marrow following cord allogeneic transplantation as therapy for second relapse acute promyelocytic leukemia in a pediatric patient.

Satiro N De Oliveira1,2, Roy L Kao2, Andrew Pham3, LaMarr Taylor Smith2, Pamela Kempert1,2, Theodore B Moore1,2.   

Abstract

Optimal therapy for relapsed APL in pediatric patients is controversial. Allogeneic HSCT is an alternative, with event-free survival of 70-75%. We report a pediatric patient with APL who relapsed 28 months after CBT from her sibling and then was treated with BMT from the same donor. Bone marrow was selected for higher cell dose, donor availability, and partial donor chimerism. Persistent molecular remission was achieved, currently at 65 months after BMT. This case suggests the potential role of GVL activity in APL and illustrates the use of different cell sources from the same donor in allogeneic transplantation for pediatric patients.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  acute promyelocytic leukemia; bone marrow transplant; graft-versus-leukemia; umbilical cord blood

Mesh：

Substances：

Year:  2016        PMID： 26849401      PMCID： PMC4807975          DOI： 10.1111/petr.12677

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN： 1397-3142


  23 in total

1.  Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia.

Authors:  B N Savani; S Mielke; S Adams; M Uribe; K Rezvani; A S M Yong; J Zeilah; R Kurlander; R Srinivasan; R Childs; N Hensel; A J Barrett
Journal:  Leukemia       Date:  2007-08-02       Impact factor: 11.528

2.  [Reduced-intensity stem cell transplantation using allogeneic peripheral blood stem cells from the same donor for relapsed leukemia after bone marrow transplantation].

Authors:  Fumiko Kuroki; Hiroaki Goto; Masakatsu Yanagimachi; Ryosuke Kajiwara; Hisaki Fujii; Sakurako Isaki; Hiroyuki Takahashi; Koichiro Ikuta; Shumpei Yokota
Journal:  Rinsho Ketsueki       Date:  2006-07

3.  Second allogeneic transplants for leukemia using blood instead of bone marrow as a source of hemopoietic cells.

Authors:  J A Russell; T Bowen; C Brown; J Luider; J D Ruether; D Stewart; K Jorgenson; M J Coppes; A R Turner; L Larratt; A Chaudhry; K Booth; M C Poon; J Klassen
Journal:  Bone Marrow Transplant       Date:  1996-09       Impact factor: 5.483

4.  Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant.

Authors:  M Eapen; S A Giralt; M M Horowitz; J P Klein; J E Wagner; M-J Zhang; M S Tallman; D I Marks; B M Camitta; R E Champlin; O Ringdén; C N Bredeson; R Martino; R P Gale; M S Cairo; M R Litzow; M deLima
Journal:  Bone Marrow Transplant       Date:  2004-10       Impact factor: 5.483

5.  Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia.

Authors:  Soheil Meshinchi; Wendy M Leisenring; Paul A Carpenter; Ann E Woolfrey; Eric L Sievers; Jerald P Radich; Jean E Sanders
Journal:  Biol Blood Marrow Transplant       Date:  2003-11       Impact factor: 5.742

6.  Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia.

Authors:  Christopher C Dvorak; Rajni Agarwal; Gary V Dahl; John J Gregory; James H Feusner
Journal:  Biol Blood Marrow Transplant       Date:  2008-07       Impact factor: 5.742

Review 7.  Umbilical cord blood transplantation--how, when and for whom?

Authors:  Yossi Cohen; Arnon Nagler
Journal:  Blood Rev       Date:  2004-09       Impact factor: 8.250

8.  Hematopoietic stem cell transplantation for acute promyelocytic leukemia in second or third complete remission: a retrospective analysis in the Nagoya Blood and Marrow Transplantation Group.

Authors:  Akio Kohno; Yoshihisa Morishita; Hiroatsu Iida; Masamitsu Yanada; Toshiki Uchida; Motohiro Hamaguchi; Masashi Sawa; Isamu Sugiura; Kazuhito Yamamoto; Shuichi Mizuta; Hiroshi Sao; Tomoki Naoe; Koichi Miyamura
Journal:  Int J Hematol       Date:  2008-02-28       Impact factor: 2.490

Review 9.  Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution.

Authors:  Julia A Brown; Vassiliki A Boussiotis
Journal:  Clin Immunol       Date:  2008-04-18       Impact factor: 3.969

Review 10.  Which donor or graft source should you choose for the strongest GVL? Is there really any difference.

Authors:  Daniel Weisdorf
Journal:  Best Pract Res Clin Haematol       Date:  2013-10-15       Impact factor: 3.020
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.